603 related articles for article (PubMed ID: 22492479)
1. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
Schwartz AV; Bauer DC; Cummings SR; Cauley JA; Ensrud KE; Palermo L; Wallace RB; Hochberg MC; Feldstein AC; Lombardi A; Black DM;
J Bone Miner Res; 2010 May; 25(5):976-82. PubMed ID: 20200926
[TBL] [Abstract][Full Text] [Related]
3. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system.
Leslie WD; Lix LM;
J Bone Miner Res; 2011 Mar; 26(3):460-7. PubMed ID: 20839285
[TBL] [Abstract][Full Text] [Related]
4. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
5. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
6. FRAX and risk of vertebral fractures: the fracture intervention trial.
Donaldson MG; Palermo L; Schousboe JT; Ensrud KE; Hochberg MC; Cummings SR
J Bone Miner Res; 2009 Nov; 24(11):1793-9. PubMed ID: 19419318
[TBL] [Abstract][Full Text] [Related]
7. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
8. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
9. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
[TBL] [Abstract][Full Text] [Related]
10. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
[TBL] [Abstract][Full Text] [Related]
13. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
15. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
16. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
Jamal SA; Bauer DC; Ensrud KE; Cauley JA; Hochberg M; Ishani A; Cummings SR
J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862
[TBL] [Abstract][Full Text] [Related]
17. Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures.
Ahmed LA; Shigdel R; Joakimsen RM; Eldevik OP; Eriksen EF; Ghasem-Zadeh A; Bala Y; Zebaze R; Seeman E; Bjørnerem Å
Osteoporos Int; 2015 Aug; 26(8):2137-46. PubMed ID: 25876879
[TBL] [Abstract][Full Text] [Related]
18. [The fracture risk assessment tool (FRAXTM), where are we in Tunisia?].
Zrour-Hassen S; Jguirim M; Guezguez M; Mnif H; Younes M; Bejia I; Touzi M; Abid A; Essabah H; Bergaoui N
Tunis Med; 2011 Feb; 89(2):136-41. PubMed ID: 21308620
[TBL] [Abstract][Full Text] [Related]
19. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.
Quandt SA; Thompson DE; Schneider DL; Nevitt MC; Black DM;
Mayo Clin Proc; 2005 Mar; 80(3):343-9. PubMed ID: 15757015
[TBL] [Abstract][Full Text] [Related]
20. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool.
Trémollieres FA; Pouillès JM; Drewniak N; Laparra J; Ribot CA; Dargent-Molina P
J Bone Miner Res; 2010 May; 25(5):1002-9. PubMed ID: 20200927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
